Elucid has raised $80 million in Series C financing led by Elevage Medical Technologies to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease.

This round brings the company’s total funding to $121 million since inception.

We see a significant market need for AI-powered cardiovascular software and are excited to partner with Elucid to help improve the diagnosis and management of heart disease and benefit patients worldwide,” said Dr. Evan Melrose, CEO of Elevage.

Elucid addresses the need for new objective, non-invasive diagnostic methods that more accurately quantify and characterize plaque and its potential impact based on actual histology (the microscopic structure of organic tissue).

Elucid’s software is the only FDA-cleared non-invasive tool able to accurately characterize arterial plaque, simulating what pathologists would see under a microscope and establishing a histologic ground truth. The company is also pursuing an indication for non-invasive measurement of fractional flow reserve (FFRCT), uniquely derived from its PlaqueIQ technology, to measure coronary blockages and the extent of ischemia.